Wall Street analysts polled by Zacks Research have given Agenus Inc. (NASDAQ:AGEN) a rating of 1 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 3 brokerages surveyed.
Shares of clinical-stage biopharma Agenus (NASDAQ:AGEN) have been on fire since the company acquired 4-Antibody in February 2014, allowing it to greatly expand its activities in the burgeoning field of immuno-oncology.
[ZACKS] Agenus Inc (NASDAQ:AGEN)(TREND ANALYSIS) shares were up 4% on the extension of its existing collaboration and license agreement with Merck MRK for the discovery and development of therapeutic antibodies to Merck's proprietary immune ...
Agenus Inc. (NASDAQ:AGEN) has lost 3.16% during the past week and dropped 17.76% in the last 4 weeks. The shares have outperformed the S&P 500 by 2.76% in the past week but underperformed the index by 13.22% in the last 4 weeks.
What: Amid an industrywide sell-off, shares in the biotech company Agenus (NASDAQ:AGEN) jumped by 10% on the open today after the company announced that positive data from a key trial was reported in the New England Journal of Medicine.